Whole-Food Plant-Based Diet Aids Men with Prostate Cancer

Why It Matters

Weight gain is a common side effect of ADT that worsens cardiovascular risk and may accelerate cancer progression; a proven dietary approach offers a low‑cost, non‑pharmacologic method to counteract these effects. Sustained fat loss can improve survival odds and quality of life for a growing cohort of prostate‑cancer patients.

Key Takeaways

• WFPB diet led to ~8 lb extra loss vs. counseling in 6 months.
• BMI dropped 1.78 kg/m² more than control after six months.
• Fat mass reduction 3.8 kg greater in diet group at study end.
• Coaching and meal delivery critical to sustained weight loss success.

Pulse Analysis

Androgen‑deprivation therapy remains a cornerstone for advanced prostate cancer, yet it carries a notorious side‑effect profile that includes rapid weight gain, insulin resistance, and heightened cardiovascular risk. As the population ages, the proportion of men entering treatment with obesity is climbing, amplifying concerns about disease progression and comorbidities. Clinicians have long sought adjunctive strategies that can blunt these metabolic derangements without adding drug burden, positioning nutrition as a promising, yet under‑utilized, lever.

The ASCO‑presented trial enrolled 60 men with a median age of 73 and baseline BMI ≥ 27 kg/m², randomizing them to a whole‑food plant‑based diet with structured meal delivery and coaching versus standard dietitian counseling. By week 26, participants on the WFPB regimen lost an average of 6.1 kg compared with 2.5 kg in the control arm, translating to roughly 8 lb of additional weight loss. Crucially, the diet group experienced superior reductions in BMI (‑1.78 kg/m² vs. ‑0.18 kg/m²) and fat mass (‑3.8 kg vs. ‑0.93 kg), while lean mass loss was modest and transient. Researchers attribute the pronounced effect to the combination of whole‑food emphasis—eliminating processed animal products—and intensive behavioral coaching that reinforced sustainable eating habits.

Beyond the immediate weight outcomes, the study opens avenues for integrating plant‑based nutrition into standard oncology protocols. Future analyses of inflammatory markers, metabolomics, and gut microbiota will clarify mechanistic pathways, potentially aligning dietary therapy with emerging pharmacologic agents such as GLP‑1 agonists. For health systems, the model offers a cost‑effective complement to existing supportive care, reducing reliance on expensive medications while empowering patients to take active roles in their treatment journey. As evidence accumulates, whole‑food plant‑based diets could become a recommended component of ADT management, reshaping survivorship standards for prostate‑cancer care.